Clinical trials: SARS Pneumonia
COVID-19
Characteristics of SARS-CoV-2 Reinfection
As the COVID-19 pandemic continues and the number of individuals with previous infection rises, numbers of SARS-CoV-2 reinfection are increasing.
- Trial name
- NCT05748262
- Where
- China
- Volunteers
- 1,144 people
- Sponsor
- Jiming Zhang
COVID-19, Hypoxemic Respiratory Failure
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
Coronavirus disease (COVID-19) can result in severe hypoxemic respiratory failure that ultimately may require invasive mechanical ventilation in the Intensive Care Unit (ICU).
- Trial name
- NORMO2 (NCT06033560)
- Testing
- High flow nasal oxygen (HFNO, more than 15 L/min)
- Where
- Netherlands
- Volunteers
- 6,000 people
- Sponsor
- Amsterdam UMC, location VUmc
COVID-19, Vaccines
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
The safety and immunogenicity of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
- Trial name
- NCT05576623
- Testing
- AdCLD-CoV19-1 OMI (Part A), AdCLD-CoV19-1 OMI (Part B)
- Where
- 7 sites in South Korea
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
Covid19, SARS-CoV2 Infection
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose
- Trial name
- NCT05054218
- Testing
- mRNA-1273
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
SARS-CoV-2 Infections, Respiratory Failure With Hypoxia
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example.
- Trial name
- QUANTICO-PRO (NCT05278390)
- Testing
- Thoracic CT scan
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
SARS CoV 2 Infection
Recovering From COVID-19
Following the success of pilot data trialling a virtual community-based remote monitoring model, using Bluetooth enabled pulse oximeters, which demonstrated a saving of 300 bed spaces over a three week period,9 a nationwide…
- Trial name
- OVER-COVID (NCT05302960)
- Testing
- Fitbit
- Sponsor
- Imperial College London
Coronavirus Disease-2019 (COVID-19)
Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans
The emergence \& rapid spread of the coronavirus disease 2019 (COVID-19) since December 2019 across 188 countries globally has become a major public health crisis.
- Trial name
- NCT04649515
- Testing
- TY027, 0.9% saline
- Where
- Singapore
- Volunteers
- 17 people
- Sponsor
- Tychan Pte Ltd.
SARS Virus, SARS-CoV-2
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of…
- Conditions
- SARS Virus, SARS-CoV-2, COVID-19
- Trial name
- PLASM-AR (NCT04383535)
- Testing
- Convalescent SARS COVID-19 plasma
- Where
- Argentina
- Volunteers
- 333 people
- Sponsor
- Hospital Italiano de Buenos Aires
COVID-19, SARS-CoV-2 Infection
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18-60 years old…
- Trial name
- NCT06381843
- Testing
- Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Covid19, ME/CFS
Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) study is a CDC-funded COVID-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have…
- Conditions
- Covid19, ME/CFS, SARS COV2, Novel Coronavirus Infection
- Trial name
- INSPIRE (NCT04610515)
- Where
- 8 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Rush University Medical Center
Covid19
Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19
Introduction: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), the new coronavirus, causes a disease called COVID-19 that can trigger aggressive inflammatory responses.
- Trial name
- TRIVID (NCT04937543)
- Testing
- inhaled beclametasone, Inahaled beclomethasone / formoterol / glycopyrronium
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection
The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with…
- Trial name
- NCT04330495
- Testing
- Hidroxicloroquina, Control group
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
SARS-CoV 2, SARS Pneumonia
Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth
This study seeks to assess the impact of physical and pulmonary rehabilitation on patients who have been diagnosed with COVID-19 in the short and long term in hopes of establishing a best practices protocol for treatment of…
- Trial name
- NCT04385901
- Testing
- Therapy Intervention
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Missouri-Columbia
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
COVID-19
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people.
- Trial name
- NCT05621239
- Testing
- BNT162b2
- Where
- Indonesia
- Volunteers
- 260 people
- Sponsor
- Pfizer
Coronavirus Infections, Coronavirus Sars-Associated
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and…
- Conditions
- Coronavirus Infections, Coronavirus Sars-Associated, SARS (Severe Acute Respiratory Syndrome), COVID-19
- Trial name
- NCT05054075
- Testing
- Marine liquid and fluids, Impregnation, Incubation
- Where
- 2 sites in Portugal
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Universidade do Porto
Covid19
Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)
This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial…
- Trial name
- NCT04480138
- Testing
- Pegylated Interferon-α2b, Standard of Care
- Where
- 2 sites in Mexico
- Volunteers
- 7 people
- Sponsor
- Zydus Lifesciences Limited
COVID-19
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
- Trial name
- NCT04422678
- Testing
- Imatinib Mesylate, Standard of Care
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Covid19
Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)
SARS-CoV-2 is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, collectively called coronavirus disease-19 (COVID-19).
- Trial name
- TP-SCB-2019001 (NCT05087368)
- Testing
- ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca), CoronaVac (Sinovac Biotech), Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
- Where
- 3 sites in Brazil
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)